PTGX SEC Filing News — Protagonist Therapeutics, Inc.

Latest SEC filings for Protagonist Therapeutics, Inc. (PTGX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-02.

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is al…
Sector: Healthcare Industry: Biotechnology Market Cap: $8.7B CIK: 1377121
20
Total Filings
0
Bullish Classifications
11
Bearish Classifications
9
Insider Transactions
2
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for PTGX currently lean bearish. Of the 20 filing records displayed, 11 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
PTGX Filing Activity Snapshot 2026-05-07 — 2026-10-02
Insider Transactions (Form 4)
0 buys vs 8 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$33.58M
Dinesh Patel · 2026-08-10
225,000 shares · Form 144
Form 144 Notices
8
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for Protagonist Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 8 open-market sale and 1 gift. 8 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×8
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Gift ×1
Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.
Form 4 Open-market sale Insider Selling 2026-10-02

PTGX insider Ali Asif (Chief Financial Officer) sold 58,629 shares (~$8.31M)

Ali Asif, listed as Chief Financial Officer at Protagonist Therapeutics, Inc, reported an open-market sale of 58,629 PTGX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,229 $38.98 $359.7K
M Option exercise 28,438 $23.42 $666.0K
M Option exercise 15,650 $19.19 $300.3K
M Option exercise 5,312 $12.17 $64.6K
S Open-market sale 12,595 $141.77 $1.79M
S Open-market sale 46,034 $141.78 $6.53M
M Option exercise derivative · Stock Option (right to buy) 9,229 — —
M Option exercise derivative · Stock Option (right to buy) 28,438 — —
M Option exercise derivative · Stock Option (right to buy) 15,650 — —
M Option exercise derivative · Stock Option (right to buy) 5,312 — —
Filing: Form 4 (Insider Transaction) Insider: Ali Asif (Chief Financial Officer) Shares: 58,629 Est. Value: $8.31M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-10

PTGX insider PATEL DINESH V PH D (Director, President and CEO) sold 125,000 shares (~$18.24M)

PATEL DINESH V PH D, listed as Director, President and CEO at Protagonist Therapeutics, Inc, reported an open-market sale of 125,000 PTGX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 54,174 $21.58 $1.17M
S Open-market sale 54,174 $145.87 $7.90M
M Option exercise 63,548 $21.58 $1.37M
S Open-market sale 63,548 $146.18 $9.29M
M Option exercise 7,278 $21.58 $157.1K
S Open-market sale 7,278 $144.10 $1.05M
M Option exercise derivative · Stock Option (right to buy) 54,174 — —
M Option exercise derivative · Stock Option (right to buy) 63,548 — —
M Option exercise derivative · Stock Option (right to buy) 7,278 — —
Filing: Form 4 (Insider Transaction) Insider: PATEL DINESH V PH D (Director, President and CEO) Shares: 125,000 Est. Value: $18.24M
View on SEC EDGAR → Open Filing Document →
Form 4 Gift Tax / Compensation Filing 2026-09-08

PTGX insider Form 4 filed for equity award, exercise, or tax withholding

PATEL DINESH V PH D (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code Nature Shares Price Value
G Gift 510 — —
Filing: Form 4 (Insider Transaction) Insider: PATEL DINESH V PH D (Director, President and CEO) Shares: 510
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-12

PTGX insider PATEL DINESH V PH D (Director, President and CEO) sold 100,000 shares (~$14.89M)

PATEL DINESH V PH D, listed as Director, President and CEO at Protagonist Therapeutics, Inc, reported an open-market sale of 100,000 PTGX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 65,761 $21.58 $1.42M
S Open-market sale 65,761 $149.11 $9.81M
M Option exercise 34,239 $21.58 $738.9K
S Open-market sale 34,239 $148.52 $5.09M
M Option exercise derivative · Stock Option (right to buy) 65,761 — —
M Option exercise derivative · Stock Option (right to buy) 34,239 — —
Filing: Form 4 (Insider Transaction) Insider: PATEL DINESH V PH D (Director, President and CEO) Shares: 100,000 Est. Value: $14.89M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-25

PTGX insider Waddill William D. (Director) sold 9,000 shares (~$1.06M)

Waddill William D., listed as Director at Protagonist Therapeutics, Inc, reported an open-market sale of 9,000 PTGX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,000 $16.54 $148.9K
S Open-market sale 9,000 $117.94 $1.06M
M Option exercise derivative · Stock Option (right to buy) 9,000 — —
Filing: Form 4 (Insider Transaction) Insider: Waddill William D. (Director) Shares: 9,000 Est. Value: $1.06M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-11

PTGX insider Waddill William D. (Director) sold 9,000 shares (~$969.1K)

Waddill William D., listed as Director at Protagonist Therapeutics, Inc, reported an open-market sale of 9,000 PTGX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 3,000 $11.80 $35.4K
M Option exercise 6,000 $16.54 $99.2K
S Open-market sale 9,000 $107.68 $969.1K
M Option exercise derivative · Stock Option (right to buy) 3,000 — —
M Option exercise derivative · Stock Option (right to buy) 6,000 — —
Filing: Form 4 (Insider Transaction) Insider: Waddill William D. (Director) Shares: 9,000 Est. Value: $969.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-01

PTGX insider Waddill William D. (Director) sold 9,000 shares (~$896.8K)

Waddill William D., listed as Director at Protagonist Therapeutics, Inc, reported an open-market sale of 9,000 PTGX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 9,000 $11.80 $106.2K
S Open-market sale 9,000 $99.64 $896.8K
M Option exercise derivative · Stock Option (right to buy) 9,000 — —
Filing: Form 4 (Insider Transaction) Insider: Waddill William D. (Director) Shares: 9,000 Est. Value: $896.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-12

PTGX insider PATEL DINESH V PH D (Director, President and CEO) sold 75,000 shares (~$7.51M)

PATEL DINESH V PH D, listed as Director, President and CEO at Protagonist Therapeutics, Inc, reported an open-market sale of 75,000 PTGX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 75,000 $21.58 $1.62M
S Open-market sale 75,000 $100.12 $7.51M
M Option exercise derivative · Stock Option (right to buy) 75,000 — —
Filing: Form 4 (Insider Transaction) Insider: PATEL DINESH V PH D (Director, President and CEO) Shares: 75,000 Est. Value: $7.51M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-11

PTGX insider Giraudo Bryan (Director) sold 59,130 shares (~$5.92M)

Giraudo Bryan, listed as Director at Protagonist Therapeutics, Inc, reported an open-market sale of 59,130 PTGX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 24,000 $6.45 $154.8K
M Option exercise 12,000 $6.98 $83.8K
S Open-market sale 36,000 $100.14 $3.61M
S Open-market sale 12,000 $100.07 $1.20M
S Open-market sale 6,000 $100.00 $600.0K
S Open-market sale 5,130 $100.00 $513.0K
M Option exercise derivative · Stock Option (right to buy) 24,000 — —
M Option exercise derivative · Stock Option (right to buy) 12,000 — —
Filing: Form 4 (Insider Transaction) Insider: Giraudo Bryan (Director) Shares: 59,130 Est. Value: $5.92M
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 8 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Protagonist Therapeutics, Inc. has 8 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Large Proposed Insider Sale 2026-09-30

PTGX Form 144 filed for proposed insider sale by ASIF ALI (58,629 shares) ~$8.26M

ASIF ALI filed a Form 144 with the SEC indicating intent to sell PTGX (Protagonist Therapeutics, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: ASIF ALI Shares: 58,629 Est. Value: $8.26M
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-10

PTGX Form 144 filed for proposed insider sale by Dinesh Patel (225,000 shares) ~$33.58M

Dinesh Patel filed a Form 144 with the SEC indicating intent to sell PTGX (Protagonist Therapeutics, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Dinesh Patel Shares: 225,000 Est. Value: $33.58M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-23

PTGX Form 144 filed for proposed insider sale by WILLIAM WADDILL (9,000 shares) ~$1.04M

WILLIAM WADDILL filed a Form 144 with the SEC indicating intent to sell PTGX (Protagonist Therapeutics, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: WILLIAM WADDILL Shares: 9,000 Est. Value: $1.04M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-10

PTGX Form 144 filed for proposed insider sale by WILLIAM WADDILL (9,000 shares) ~$952.8K

WILLIAM WADDILL filed a Form 144 with the SEC indicating intent to sell PTGX (Protagonist Therapeutics, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: WILLIAM WADDILL Shares: 9,000 Est. Value: $952.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-05-29

PTGX Form 144 filed for proposed insider sale by WILLIAM WADDILL (9,000 shares) ~$903.7K

WILLIAM WADDILL filed a Form 144 with the SEC indicating intent to sell PTGX (Protagonist Therapeutics, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: WILLIAM WADDILL Shares: 9,000 Est. Value: $903.7K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-05-12

PTGX Form 144 filed for proposed insider sale by Dinesh Patel (75,000 shares) ~$7.76M

Dinesh Patel filed a Form 144 with the SEC indicating intent to sell PTGX (Protagonist Therapeutics, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Dinesh Patel Shares: 75,000 Est. Value: $7.76M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-05-08

PTGX Form 144 filed for proposed insider sale by BRYAN M & COURTNEY L GIRAUDO RT (11,130 shares) ~$1.11M

BRYAN M & COURTNEY L GIRAUDO RT filed a Form 144 with the SEC indicating intent to sell PTGX (Protagonist Therapeutics, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: BRYAN M & COURTNEY L GIRAUDO RT Shares: 11,130 Est. Value: $1.11M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-05-07

PTGX Form 144 filed for proposed insider sale by BRYAN GIRAUDO (36,000 shares) ~$3.60M

BRYAN GIRAUDO filed a Form 144 with the SEC indicating intent to sell PTGX (Protagonist Therapeutics, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: BRYAN GIRAUDO Shares: 36,000 Est. Value: $3.60M
View on SEC EDGAR → Open Filing Document →
Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Protagonist Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-05

PTGX filed 8-K — material company event

Protagonist Therapeutics, Inc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-18

PTGX filed 8-K — material company event

Protagonist Therapeutics, Inc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Protagonist Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

PTGX filed Quarterly Report (10-Q)

Protagonist Therapeutics, Inc filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Protagonist Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on PTGX. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — PTGX SEC Filings

More Tools for PTGX

PTGX Full Stock Analysis PTGX Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper PTGX analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the PTGX stock analysis page.

PTGX Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer